Nektar Therapeutics Shareholders Urged to Seek Compensation for Losses

2026-04-09 08:59:03

Abstract generation in progress

Robbins LLP has filed a class action lawsuit against Nektar Therapeutics on behalf of investors who purchased securities between February 26, 2025, and December 15, 2025. The lawsuit alleges that Nektar misled investors about the REZOLVE-AA clinical trial for its alopecia drug, failing to disclose issues with enrollment and protocol that led to overstated prospects. The trial ultimately failed to meet statistical significance, causing Nektar’s stock price to fall and resulting in investor losses.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes